Drug intelligence / Profile preview

VX-864

Development stage
Discontinued
Lead developer
Vertex
Modality
Small Molecules
Administration
Oral
01

Overview

VX-864 is an investigational small molecule developed by Vertex Pharmaceuticals for the treatment of alpha-1 antitrypsin deficiency (AATD), a genetic disorder characterized by misfolding and polymerization of the Z variant of alpha-1 antitrypsin (AAT) protein. VX-864 acts as a corrector molecule, designed to promote proper folding of the mutant Z-AAT protein, thereby increasing plasma levels of functional AAT. Clinical studies demonstrated that VX-864 could significantly increase circulating functional AAT levels in patients with the PiZZ genotype; however, the magnitude of effect was considered insufficient for substantial clinical benefit. The development program was discontinued due to limited efficacy and non-serious rash events observed in some patients[3][6][8].

Other names
vx 864vx864vx-864
02

Targets

SERPINA1 Z (Alpha-1-antitrypsin Z variant protein)

Beyond the preview

Go deeper on VX-864.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on VX-864.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call